Lipiodol opacifies vessels and body structures in the path of the flow of the contrast medium, permitting visualization of the internal structures.

LIPIODOL is an oil-based radiopaque contrast agent approved for:

• Hysterosalpingography in adults
• Lymphography in both adults and pediatric patients
• Selective hepatic intra-arterial imaging of tumors in adults with known hepatocellular carcinoma (HCC)

Adults:

• unilateral lymphography of the upper extremities 2 to 4 mL
• unilateral lymphography of the lower extremities 6 to 8 mL
• penile lymphography 2 to 3 mL
• cervical lymphography 1 to 2 mL

Pediatric patients:

• Inject a minimum of 1 mL to a maximum of 6 mL according to the anatomical area to be visualized. Do not exceed 0.25 mL/kg.

General

• Hypersensitivity, embolisms, liver dysfunction, thyroid disorders, fever, nausea, abdominal pain

By Indication

• Hysterosalpingography: Pain, infection exacerbation, peritonitis
• Lymphography: Edema, dermatitis, lymphedema worsening
• Hepatic Injection: Thrombosis, liver enzyme elevation, vomiting

General: Hypersensitivity, hyperthyroidism, trauma, recent bleeding

Hysterosalpingography: Pregnancy, pelvic inflammatory disease, cervical erosion, etc.

Lymphography: Cardiac shunt, pulmonary disease, lymphatic surgery or damage

Hepatic injection: Dilated bile ducts (unless externally drained)

Pulmonary and Cerebral Embolism

• Serious or fatal embolisms possible from improper injection.
• Avoid in patients with lung or heart impairment.

 Hypersensitivity Reactions

• Risk of anaphylactic/anaphylactoid reactions, especially in patients with allergies or asthma.
• Requires availability of resuscitation-trained personnel and emergency treatment setup.

Chronic Liver Disease

• May worsen portal hypertension, hepatic failure, or hepatic ischemia.

Thyroid Dysfunction

• May cause hypo- or hyperthyroidism.
• Monitor thyroid function post-administration, especially in pregnant or breastfeeding women and infants.